Summary

Overview
Global Prostate Health Market reached US$ XX billion in 2022 and is expected to reach US$ XX million by 2030 growing at a CAGR of XX% during the forecast period 2023-2030.
The three primary conditions can affect the prostate namely benign prostatic hyperplasia (BPH) which is an expansion of the prostate gland brought on by aging, prostatitis, an infection or inflammation of the prostate, and prostate cancer which is the development of malignant cells within the prostate that have the potential to spread outside the gland and impact other body organs.
The prostate consists of connective tissues and glandular tissues that add fluid to the semen, and its muscles help push semen through the urethra. Acute prostatitis is caused by an infection, usually by bacteria, and results in the sudden onset of painful urination, a small stream, and often fever and chills.
Market Dynamics
Increasing drug approvals
The increasing drug approvals act as a significant driver for market growth. The prostate is responsible for producing seminal fluid that nourishes and transports sperm. It is vulnerable to three main conditions that is prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer.
For instance, in March 2023, the Chinese National Medical Products Administration (NMPA) approved the oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Additionally, in August 2023, the U.S. FDA approved AKEEGA (Niraparib and Abiraterone Acetate). It is the first and only dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.
Also, in March 2022, Novartis, a Swiss-American multinational pharmaceutical corporation received FDA approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the therapy of adult individuals suffering from a specific kind of progressive cancer named prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer
Furthermore, significant growth drivers such as the rising prevalence of prostate cancers, and increasing clinical trials for treatment drugs are expected to drive the market in the forecast period.
Stringent regulatory policies
The presence of stringent regulatory authority bodies approving the usage and commercialization of drugs or biologics employed in treating the prostate health market is hampering global market growth. For instance, the European Medicines Agency (EMA), an agency of the European Union in command of the evaluation and surveillance of pharmaceutical developments, and the U.S Food and Drug Administration (USFDA), a nationwide agency of the Department of Health and Human Services are prominent regulatory authoritative bodies among others.
Segment Analysis
The global prostate health market is segmented based on indication, treatment, end users, and region.
The radiation therapy segment accounted for approximately 41.8% of the market share
The radiation therapy segment is expected to hold the largest market share over the period forecast. Radiation therapy uses high-energy rays or particles to kill cancer cells. It is used depending on the stage of the prostate cancer and other factors. A total of 185 clinical trials were conducted for prostate cancer.
For instance, according to Clinicaltrials.gov, on April 4, 2023, the Proton Collaborative Group conducted a clinical trial on hypo-fractionated radiation therapy with or without androgen suppression for intermediate risk prostate cancer. It is currently in phase 3 trial and the expected study completion date is December 2025.
Additionally, on April 28, 2021, Lund University Hospital conducted a clinical trial on personalized radiotherapy for biochemical recurrence of prostate cancer after prostatectomy. It is currently in phase 3 trial. Hence, due to the above factors, the segment is expected to hold the largest market share.
Geographical Analysis
North America is expected to hold a significant position in the global prostate health market share
The global prostate health market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa.
North America has maintained a significant market proportion due to factors such as the rising prevalence of prostate cancer, drug approvals, and increasing healthcare expenditure, this trend is anticipated to continue throughout the forecast period.
For instance, the American Cancer Society estimates for prostate cancer in the United States for 2023 are around 288,300 new cases of prostate cancer and about 34,700 deaths from prostate cancer
Additionally, in November 2023, Astellas Pharma Inc. and Pfizer Inc. received approval from the U.S. FDA of a supplemental New Drug Application for XTANDI (enzalutamide) for prostate cancer.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the global prostate health market. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular diagnoses, treatment, drug launches, and consultations worldwide. With the outbreak of the pandemic, many pharmaceutical or medical device manufacturing units faced labor shortages and were unable to travel to work due to lockdown restrictions. Therefore, owing to the above factors, the prostate health market is expected to be moderately affected over the forecast period.
Market Segmentation
By Indication
• Prostate cancer
• Benign prostatic hyperplasia (BPH)
• Prostatitis
By Treatment
• Radiation Therapy
• Surgery
• Chemotherapy
• Immunotherapy
• Hormone Therapy
• Targeted Drug Therapy
By End Users
• Hospitals
• Oncology Centers
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Pfizer Inc., Astellas Pharma Inc., Lupin Ltd, Eli Lilly and Company, Johnson & Johnson, BDR Pharmaceuticals Internationals Pvt. Ltd, Bayer AG, AstraZeneca Plc, Sanofi S.A, and Fusion Pharmaceuticals Inc. among others.
Key Developments
• In February 2023, Fusion Pharmaceuticals Inc. declared the acquisition from RadioMedix, Inc. of the investigational new drug application for an ongoing Phase 2 clinical trial evaluating 225Ac-PSMA.
• In January 2023, BDR Pharmaceuticals launched the generic Apalutamide in India to treat metastatic castration sensitive prostate cancer.
Why Purchase the Report?
• To visualize the global prostate health market segmentation based on indication, treatment, end users and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of global prostate health market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global prostate health market report would provide approximately 61 tables, 59 figures, and 185 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Indication
3.2. Snippet by Treatment
3.3. Snippet by End User
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing drug approvals
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent regulatory approvals
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Indication
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
7.1.2. Market Attractiveness Index, By Indication
7.2. Prostate cancer *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Benign prostatic hyperplasia (BPH)
7.4. Prostatitis
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Radiation Therapy *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chemotherapy
8.4. Surgery
8.5. Immunotherapy
8.6. Hormone Therapy
8.7. Targeted Drug Therapy
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals *
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Oncology Centers
9.4. Ambulatory Surgical Centers
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Astellas Pharma Inc.
12.3. Lupin Ltd
12.4. Eli Lilly and Company
12.5. Johnson & Johnson
12.6. BDR Pharmaceuticals Internationals Pvt. Ltd
12.7. Bayer AG
12.8. AstraZeneca Plc
12.9. Sanofi S.A
12.10. Fusion Pharmaceuticals Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us